The company will utilise Qureight’s AI technology to undergo studies across a variety of complex lung diseases
News
Crescendo widens pivotal solid tumour therapy trial
The CB307 study expansion involves the addition of a new pembrolizumab combination cohort
EMA positive opinion for ViiV’s cabotegravir
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Janssen’s Talvey receives positive CHMP opinion
The treatment is a monotherapy for treating adult patients with refractory or relapsed multiple myeloma
Teva UK launches GoResp Digihaler
The inhaler supports appropriate individuals presenting with asthma and chronic obstructive pulmonary disease
CatalYm highlights GDF-15 as main anti-PD-1 resistance factor
Data underlines the significance of the company’s anti-GDF-15 antibody candidate, visugromab
UCB announces EMA bimekizumab verdict
In two studies the therapy demonstrated improvements when compared with the placebo
Grifols announces phase 3 progress for Albutein
Therapy has the potential to decrease mortality rates in patients with decompensated cirrhosis
Members of the Alliance for Genomic Discovery revealed
Illumina and Nashville Biosciences’ have announced AbbVie, Amgen, AstraZeneca, Bayer and Merck as founding members
Glaucoma therapy Roclanda launched by Santen
By combining both netarsudil and latanoprost treatment, Roclanda reduces intraocular pressure
Chemspace and Arrayjet link up to boost drug discovery
The partnership will expand Arrayjet’s small molecule microarray drug discovery offerings
ADDF reflects on Eli Lilly’s donanemab
Company’s phase 3 research showed the importance of running biomarker-powered clinical trials
TauRx’s deliver Alzheimer’s disease therapy results
Company’s hydromethylthionine mesylate therapy reduced neurodegeneration during pivotal trial
Cannabinoid company expands into oncology
OCTP develops cannabinoid medicines and is looking at potential treatment of cancer malignancies
Positive data for Caribou Biosciences’ CB-010 candidate
CAR-T cell therapy being researched among patients with relapsed or refractory B cell non-Hodgkin lymphoma
